Modality
Peptide
MOA
EZH2i
Target
GPRC5D
Pathway
NF-κB
CMLRB
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
~Jul 2021
→ ~Oct 2022
Phase 2
Jan 2023
→ Jun 2028
Phase 2Current
NCT08259675
1,972 pts·CML
2024-04→2028-06·Completed
NCT04821093
810 pts·CML
2023-01→2027-08·Recruiting
2,782 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-121.4y awayPh2 Data· CML
2028-06-242.2y awayPh2 Data· CML
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2027-08-12 · 1.4y away
CML
Ph2 Data
2028-06-24 · 2.2y away
CML
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08259675 | Phase 2 | CML | Completed | 1972 | BodyWt |
| NCT04821093 | Phase 2 | CML | Recruiting | 810 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |